Precision Medicine Liaisons Boost Biomarker Testing By 35%
Download PDF
Enhancing the adoption of PD-L1 biomarker testing by 35% to empower HCPs and improve outcomes for oncology patients through strategic collaboration and precision medicine expertise.
OUR TASK
The challenge was clear: Improve the adoption of PD-L1 biomarker testing within oncology practices to help patients access more personalized, effective treatment options. By leveraging a specialized team of Amplity precision medicine liaisons (PMLs), we aimed to bridge the knowledge gap, demonstrate the value of biomarker testing, and work collaboratively with healthcare teams to integrate this critical tool into routine care, ultimately driving better outcomes for patients.
Precision Medicine Liaisons Boost Biomarker Testing By 35%
Download PDF
Enhancing the adoption of PD-L1 biomarker testing by 35% to empower HCPs and improve outcomes for oncology patients through strategic collaboration and precision medicine expertise.
OUR TASK
The challenge was clear: Improve the adoption of PD-L1 biomarker testing within oncology practices to help patients access more personalized, effective treatment options. By leveraging a specialized team of Amplity precision medicine liaisons (PMLs), we aimed to bridge the knowledge gap, demonstrate the value of biomarker testing, and work collaboratively with healthcare teams to integrate this critical tool into routine care, ultimately driving better outcomes for patients.
Download PDF
The Power of This Partnership
35%
Increased Biomarker Testing In 12 Months
50%
Test Turnaround Time From 10 To 5 Days
The Ask
CLIENT
Global
Large BioPharma
Educate Providers On Biomarker Testing
Ensure oncologists, pathologists, and lab professionals understand the significance of PD-L1 biomarker testing in identifying targeted therapies for their patients. Education focused on simplifying complex concepts and connecting them to real-world patient benefits.
Increase Adoption Through Tailored Strategies
Implement strategies that address barriers to adoption, including a lack of awareness, concerns about workflow integration, and limited access to testing resources.
Demonstrate Real Impact
Showcase the tangible benefits of biomarker testing, not just for patients but also for practices aiming to deliver cutting-edge care and improve treatment outcomes.
The Approach
TOOLS
Precision Medicine Liaison
Deploy Precision Medicine Liaisons As Trusted Advisors
Amplity deployed a team of PMLs who worked one-on-one with oncology practices. These experts served as dedicated partners, offering insights, training, and hands-on support to address specific challenges around PD-L1 biomarker testing.
Custom Education & Resources
Created tailored educational materials and workshops to fit the needs of each team. Resources ranged from clinical case studies to workflow optimization guides, ensuring a comprehensive understanding of the value of biomarker testing.
Collaborative Problem-Solving
Rather than taking a one-size-fits-all approach, the team fostered collaboration with HCPs to identify barriers and co-develop solutions, ensuring seamless integration of biomarker testing into daily operations.
The Results
OUTCOME
HCP Behavior Change
Client Satisfaction
Fast Tracked Care
35% Boost In Biomarker Testing Adoption
Within 12 months, oncology practices supported by precision medicine liaisons achieved a remarkable 35% increase in PD-L1 biomarker testing rates. This boost directly expanded access to personalized medicine tools and empowered providers to better match patients with targeted therapies.
50% Improvement In PD-L1 Scoring Accuracy
Over 500 clinicians were trained through tailored educational programs, resulting in a 50% increase in accurate PD-L1 scoring. This improvement maximized opportunities for patients to receive therapies specifically tailored to their biomarker profiles, enhancing treatment efficacy.
Test Turnaround Time Reduced By Half
Streamlined workflows and reduced test result turnaround times from 10 days to just 5 days. Faster results enabled oncology teams to make quicker, more informed treatment decisions, improving the timeliness of care for patients.
Enhanced Clinician Expertise & Confidence
With targeted training and resources, clinicians gained deeper expertise in biomarker testing and its role in oncology care. This boost in confidence helped drive adoption and integrate precision medicine into routine practice, ultimately improving patient outcomes.
